Research
Hormonal
Short-acting GLP-1 receptor agonists are associated with an increased risk of Barrett's esophagus with dysplasia with a hazard ratio (HR) of 1.505.
Clinicians should be aware of the potential risk of Barrett's esophagus with dysplasia in patients prescribed short-acting GLP-1 RAs.
StrongSupportsmedium confidence
Barrett's with dysplasia (HR 1.505; 95% CI 1.164 to 1.946).
Why this rating
Based on a large cohort study design.
Source
Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study
Benjamin D. Liu et al. · Gut · 2023
DOI 10.1136/gutjnl-2023-329651
cohort · n=1543351Cited 38×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →